Hypophosphatasia: New Options in the Management of Alkaline Phosphatase Deficiency - Webcast

The webcast activity Hypophosphatasia: New Options in the Management of Alkaline Phosphatase Deficiency was originally presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, on April 3, 2016.

Expert faculty discussed recent advances in the practical applications of new tools and potential strategies in treatment options for hypophosphatasia.

This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with bone disorders.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Describe the role of alkaline phosphatase and discuss the genetic underpinnings of hypophosphatasia
  • Evaluate clinical presentation, biochemical tests, and radiological images in the diagnosis of hypophosphatasia
  • Integrate supportive therapy to minimize disease-related sequelae in the management of hypophosphatasia
  • Apply recently approved treatment option in perinatal, infantile and juvenile-onset hypophosphatasia

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Bone and Calciotropic Hormones
Quality Improvement and Healthcare Delivery
General Endocrinology
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 ABIM MOC
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
United States

Jill H. Simmons, MD – Program Director
Associate Professor of Pediatrics
Vanderbilt University School of Medicine
Nashville, Tennessee

Nancy S. Dunbar, MD, MPH, FAAP
Director, Bone and Mineral Disorders
Assistant Professor, Pediatric Endocrinology
Connecticut Children’s Medical Center
Hartford, Connecticut

Peter J. Tebben, MD
Mayo Clinic
Departments of Internal Medicine and Pediatrics
Division of Endocrinology
Rochester, Minnesota

Michael P. Whyte MD
Medical-Scientific Director
Center for Metabolic Bone Disease and Molecular Research
Shriners Hospital for Children
St. Louis, Missouri


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Jill H. Simmons, MD: Advisory Group Member, Alexion
Michael P. Whyte, MD: Clinical Researcher, Alexion

The following faculty reported no relevant financial relationships: Nancy S. Dunbar, MD, MPH; Peter J. Tebben, MD 

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Larry Fox, MD

The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E. Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Alan Kelly, MD; Michael S. Irwig, MD; Connie B. Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 ABIM MOC
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation